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ABSTRACT  16 
Antisense oligomers (AOs) are increasingly being used for modulating RNA splicing in live cells, 17 
both for research and for therapeutic purposes. While the most common intended effect of these 18 
AOs is to induce skipping of whole exons, rare examples are emerging of AOs that induce skipping 19 
of only part of an exon, through activation of an internal cryptic splice site. In this report, we 20 
examined seven such examples of AO-induced cryptic splice site activation – five new examples 21 
from our own experiments and three from reports published by others. We modelled the predicted 22 
effects that AO binding would have on the secondary structure of each of the RNA targets, and 23 
how these alterations would in turn affect the accessibility of the RNA to splice factors. We 24 
observed that a common predicted effect of AO binding was a disruption to the exon definition 25 
signal within the exon’s excluded segment. 26 
Introduction  27 
The process of pre-mRNA splicing is a fundamental aspect of gene regulation and function in higher 28 
eukaryotes. Pre-mRNA consists of coding regions termed exons that are intersected by non-coding 29 
regions termed introns 1. During maturation into mRNA, these non-coding regions are removed, and 30 
the exons ligated together to form a continuous message ready to be translated into a protein. Pre-31 
mRNA splicing involves a multitude of splicing factors that interact with numerous splicing motifs on 32 
the transcript 2. A large multi-protein complex called the spliceosome is responsible for the 33 
coordination of this complex set of transesterification reactions 3. 34 
The major form of the spliceosome is composed of five small nuclear ribonucleoproteins 35 
(snRNPs; U1, U2, U5 and U4/U6), as well as numerous non-snRNP proteins 4,5. The canonical 5′ 36 
splice site (5′ss) is defined by an AG|GURAGU sequence, while the 3′ splice site (3′ss) is denoted 37 
by a (Yn)-YAG| sequence (where; | = exon boundary; underlined sequence identifies invariant 38 
nucleotides; R = purine; Y = pyrimidine) 6. The branchpoint sequence, typically located approximately 39 
15 to 50 nucleotides (nt) upstream from the 3′ss, is required for U2 snRNA binding during 40 
spliceosome formation. This sequence is defined as YNCURAY (underlined sequence denotes 41 
branch formation region; bold nucleotides are highly conserved; N = any nucleotide) 6. The major 42 
spliceosome (called spliceosome hereon), along with hundreds of associated splicing factors are 43 
responsible for over 95% of all splicing reactions including the phenomenon known as alternative 44 
splicing 7-10. 45 
Alternative splicing is a process whereby multiple different transcript and protein isoforms can 46 
arise from a single protein-coding gene and is an essential element in spatial and temporal regulation 47 
of gene expression in higher eukaryotes 7. In order to achieve alternative splicing, the spliceosome 48 
must recognize and select a splice site from a variety of alternative splice sites and branchpoints 49 
within the transcript. Typically, these splice sites are well defined and have evolutionarily conserved 50 
functions. However, sometimes sequences usually ignored by the spliceosome can become 51 
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activated as splice junctions. These are known as cryptic splice sites 11 and are most often activated 52 
by mutations or errors during transcription 12. The most common causative mutations are those that 53 
abolish canonical splice sites, thus redirecting the spliceosome to either utilize a viable cryptic site 54 
nearby or exclude the exon completely from the mature mRNA 13. Cryptic splice sites may be found 55 
within both exonic and intronic regions and typically include or exclude a proportion of the intron or 56 
exon 12. Interestingly, recent data has shown that cryptic splice sites can also be activated by 57 
synthetic molecules such as antisense oligonucleotides. 58 
Antisense oligonucleotides (AOs) are small, single-stranded RNA or DNA-like synthetic 59 
molecules used to modify gene expression. These AOs can be used to downregulate gene 60 
expression through RNA silencing, redirection of pre-mRNA splicing patterns, intron retention, 61 
inhibiting translation, or RNase H-induced degradation of the target gene transcript 14. The sequence 62 
of maturing gene transcripts can also be altered by using AOs to induce removal or inclusion of an 63 
exon, as seen with current therapeutic strategies approved for the treatment of Duchenne muscular 64 
dystrophy and spinal muscular atrophy, respectively.  65 
While most splice modulating AOs are designed with the intention to enhance exon selection 66 
or induce skipping of whole exons, the occasional activation of cryptic splice sites after in vitro AO 67 
treatment has also been observed. We have reported the activation of a cryptic donor splice site 68 
after treatment with an AO targeting LMNA pre-mRNA, promoting removal of 150 nt from the end of 69 
exon 11 15. Evers et al. 16 observed that an AO targeting exon 9 in ATXN3 promoted a partial exon 9 70 
skip, activating an alternative 5’ss. A partial exon 12 skip in the HTT transcript was also detected 71 
after treatment with an AO (World Patent WO2015053624A2); once again activating a cryptic donor 72 
splice site 17. Lastly, we recently reported activation of two cryptic donor splice sites by AOs 73 
containing several locked nucleic acid residues, designed to enhance efficiency of exon skipping 74 
from the dystrophin transcript 18. 75 
In addition to the established roles that splice site motifs and exon enhancer and silencer motifs 76 
play in directing RNA splicing, there is increasing evidence of a similar role for RNA secondary 77 
structure 19-22 and of its effect on splice factor binding 23,24. While modelling the interactions of these 78 
phenomena presents a highly complex challenge, a reasonable starting point may be to assume that 79 
RNA secondary structure is generally antagonistic to splice factor binding within closed regions. 80 
In our laboratory’s quest to develop new therapeutics for debilitating genetic diseases, we have 81 
tested thousands of AOs targeted to numerous genes in a variety of cell types, but we have observed 82 
only a handful of AO-induced cryptic splicing events in the target transcripts in human cells, and a 83 
single example in mouse cells 25. In this study, we investigated the possible mechanisms by which 84 
AOs may induce cryptic splicing. We analyzed 13 AOs targeting six different human gene transcripts 85 
and found that changes to the accessibility of enhancer and silencer motifs within the transcript 86 
secondary structure appeared to play a role in many cases. The diverse nature of these changes 87 





Results and Discussion 91 
To explore the possible mechanisms behind cryptic splice site activation, we analyzed AO-induced 92 
cryptic splicing events in six different human transcripts: COL7A1, SRSF2, ATXN3, USH2A, HTT, 93 
and LMNA. Data for HTT and LMNA were obtained from the literature and analyzed together with 94 
those from the remaining transcripts. 95 
Analysis of antisense oligonucleotide treatment 96 
COL7A1 exon 15 97 
Antisense oligonucleotides were transfected into healthy human fibroblasts as cationic lipoplexes at 98 
concentrations of 100 and 50 nM to induce skipping of exon 15 from the COL7A1 pre-mRNA 99 
transcript, removing 144 nt from the full-length transcript (Fig. 1a). Subsequent RT-PCR analysis 100 
revealed both the full-length transcript and an unanticipated amplicon, smaller than full-length but 101 
larger than would be expected as a result of complete exon 15 removal. The unexplained amplicon 102 
was isolated and identified by Sanger sequencing to be missing the last 64 nucleotides from the 3’ 103 
end of exon 15. Removing 64 nt from the COL7A1 transcript would render the cryptically spliced 104 
product out-of-frame, and therefore produce a premature termination codon in exon 16. This 105 
discovery highlights the importance of investigating unexpecting splicing products after AO 106 
treatment. A new donor splice site was activated by treatment with an AO targeting COL7A1 exon 107 
15, H15A(+91+115), that resulted in cryptic splice site activation in 30% of the transcripts at both 108 
100 nM and 50 nM. Treatment with this AO did not induce other aberrant splicing products. 109 
Transfection of cells with an AO covering the authentic donor site, H15D(+14-11), did not lead to 110 
cryptic donor site activation. 111 
SRSF2 exon 2 112 
Antisense oligonucleotides were transfected into healthy human fibroblasts as cationic lipoplexes at 113 
concentrations of 100, 50 and 25 nM to induce skipping of exon 2 from the SRSF2 pre-mRNA 114 
transcript, removing 311 nt from the full-length transcript (Fig. 1b). Gel fractionation of the RT-PCR 115 
amplicons revealed several products confirmed by Sanger sequencing: full-length SRSF2-T204 116 
(ENST00000452355.7); full-length SRSF2-T208 (ENST00000585202.5); and T208 missing 65 nt from 117 
the 3’ end of exon 2. Multiple amplicons larger than 1000 nt were present, which correspond to the 118 
amplicon sizes of the transcripts SRSF2-T203 (ENST00000392485.2) and SRSF2-T202 119 
(ENST00000359995.10) (Supplementary Fig. 1a). The splicing of T202 appears to be influenced by 120 
the AOs in the same manner (Supplementary Fig. 1a). However, we were unable to isolate and 121 
identify various amplicons to confirm this. The AOs did not appear to cause exon skipping or cryptic 122 
donor site activation within the T203 transcript, most likely due to the T203 isoform containing only 123 
two exons, making both “unskippable” 26. 124 
Under normal conditions, SRSF2 transcript isoforms T202 and T203 code for proteins while 125 
T208 and T204 undergo nonsense mediated decay (NMD). After AO treatment, the expression of the 126 
cryptically spliced T208 increased with a concomitant decrease in the full-length T202. The cryptic 127 
splicing of exon 2 removes the natural termination codon from T202, T204, and T208 and exposes 128 
a new in-frame termination codon in the following exon of each transcript (Supplementary Fig. 1b).  129 
Mammalian NMD generally follows the ’50 nucleotide rule’, whereby termination codons more 130 
than 50 nt upstream of the final exon are determined premature and result in a reduction in mRNA 131 
abundance 27. Cryptic splice site activation appears to stabilize T208 as a new termination codon is 132 
created within 50 nt of the penultimate 3’ exon junction. Isoform T204 still appears to undergo NMD, 133 
as the new termination codon is exposed within the third exon of the five-exon isoform.  134 
ATXN3 exon 9 135 
Antisense oligonucleotides were transfected into healthy control human fibroblasts as cationic 136 
lipoplexes at concentrations of 400, 200, 100 and 50 nM to induce skipping of exon 9 from the 137 
ATXN3 pre-mRNA, thereby removing 97 nt from the full-length transcript (Fig. 1c). Gel fractionation 138 
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of the RT-PCR amplicons revealed two full-length product bands representing the two transcripts in 139 
the untreated sample: a larger product (533 nt) containing 21 CAG (21Q) repeats, and a slightly 140 
smaller product containing eight CAG (8Q) repeats. Complete exon 9 skipping from the 8Q transcript 141 
was observed in healthy human fibroblasts treated with H9A(+38+62) at all concentrations tested. 142 
The same AO treatment also activated a cryptic donor site, resulting in removal of 55 nt from the 8Q 143 
transcript. Treatment with H9D(+20-05) resulted solely in partial exon 9 skipping from the 8Q 144 
transcript. All amplicons were isolated and identified by Sanger sequencing.  145 
Complete and partial exon 9 skipping was observed only from the 8Q and not the 21Q 146 
transcript. Cryptic donor activation in the transcript with fewer CAG repeats dominates in some AO 147 
treatments but not others 28,29. The CAG expansion occurs in the following exon 10 that is separated 148 
by a 10 kb intron from the AO target. Numerous studies assessing AO-mediated removal of exon 9 149 
and/or exon 10 from the ATXN3 transcript reported reduced exon skipping efficiencies the larger the 150 
expansion size. Although this phenomenon is directed more towards exon 10 removal, we speculate 151 
that the CAG repeat length may influence frequency of the cryptic splice site usage. The nature of 152 
the CAG repeat allows for numerous consecutive potential serine/arginine-rich splicing factor (SRSF) 153 
2 (AGCAG) and SRSF5 (ACAGC) splice motifs. The fact that these positive exon selection sites are 154 
heavily repeated may influence exon 10, and potentially exon 9, selection and therefore susceptibility 155 
to AO-mediated exon skipping. 156 
USH2A exon 13 157 
Antisense oligonucleotides were transfected into a Huh7 cell line as cationic lipoplexes at 158 
concentrations of 200 and 50 nM to induce skipping of exon 13 from the USH2A pre-mRNA 159 
transcript (Fig. 1d). Subsequent RT-PCR analysis revealed multiple unanticipated amplicons larger 160 
than expected from the removal of exon 13 in its entirety. It was evident that multiple splicing events 161 
occurred: removal of the complete exon 13; activation of a cryptic donor; activation of a cryptic 162 
acceptor; or activation of both cryptic donor and acceptor sites within exon 13, after treatment with 163 
different AOs. Treatment with H13A(-05+20) and H13A(+70+94) resulted mainly in complete exon 13 164 
exclusion, removing 642 nt from the full-length transcript, and the activation of a cryptic acceptor 165 
site, removing 527 nt from the full-length transcript. Treatment with H13A(+136+160) and 166 
H13A(+161+183) resulted in the activation of a cryptic donor site, both on its own (missing 513 nt 167 
from the 3’ end of exon 13) and in conjunction with the cryptic acceptor site (missing 398 nt from 168 
the middle of exon 13), but did not remove the entire exon 13. We were unable to isolate and identify 169 
one of the amplicons by Sanger sequencing (labelled with an arrow in Fig. 1d). We speculate that 170 





Figure 1. Activation of cryptic splice sites by AO-mediated splice switching in four different 174 
gene transcript targets. (a) COL7A1 exon 15. (b) SRSF2 exon 2. (c) ATXN3 exon 9. (d) USH2A exon 175 
13. Reverse transcription-PCR analysis after transfection with antisense oligonucleotides (AOs), at 176 
various nM concentrations indicated above the gel image. Sanger sequencing data identifies the 177 
smaller amplicon(s) resulting from AO treatment. Blue boxes represent exons, lines between the 178 
boxes represent introns, dashed lines above and below represent various splicing events, pink boxes 179 
represent the portion of exon removed after the activation of a new cryptic splice site. Arrow indicates 180 
an amplicon that could not be succesfully isolated and sequenced. NC, negative control sequence 181 
synthesized as 2’-OMe PS; UT, untreated; 100 bp, 100 base pair DNA ladder; nM, nanomolar. 182 
Analysis of splice site scores and exonic splicing enhancer motifs masked by the 183 
examined antisense oligonucleotides 184 
Two models were employed to calculate the scores of both the canonical and cryptic splice sites 185 
activated after AO treatment: a weight matrix model, Human Splice Finder 3.1 30, and a maximum 186 
entropy model, MaxEntScan 31. No discernable pattern became evident using either model (Table 187 
1), indicating splice site scores are not the only factor influencing splice site usage. 188 
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Table 1. Comparing canonical and cryptic splice site scores using two different modeling 189 
approaches.  190 


















USH2A (13) Acceptor 88.04 80.44 8.95 -1.01 +527 
Donor 97.66 82.16 10.77 4.88 +129 
COL7A1 (15) Donor 88.19 78.49 4.01 2.97 +80 
ATXN3 (9) Donor 74.37 76.7 1.6 7.09 +42 
SRSF2 (2) Donor 73.19 72.69 -0.64 5.46 +246 
HTT* (12) Donor 83.43 92.8 7.16 8.54 +206 
LMNA* (11) Donor 98.84 88.33 8.07 2.93 +120 
 191 
Exonic splicing enhancer (ESE) motifs masked by AO binding sites were counted using 192 
ESEFinder3.0 32; (Table 2). Motifs were included when one or more motif nucleotides were masked 193 
by the targeting AO. The examined AOs were found to consistently mask SRSF1 motifs, with 194 
exception of the AO H2D(+10-12) targeting the SRSF2 donor site.  195 
Table 2. Exonic splicing enhancer motifs masked by the antisense oligonucleotides examined in this 196 
study.  197 
Gene AO nomenclature SRSF1 (SF2) SRSF2 (SC35) SRSF5 (SRp40) SRSF6 (SRp55) 
USH2A 
H13A(-05+20) 1 1 1 0 
H13A(+70+94) 1 2 0 0 
H13A(+136+160) 2 0 1 0 
H13A(+161+183) 4 1 1 1 
COL7A1 
H15A(+91+115) 5 1 1 0 
H15D(+14-11) 2 2 0 1 
ATXN3 
H9A(+38+62) 1 0 1 1 
H9A(+65+85)* 3 0 1 0 
H9D(+20-05) 1 0 2 0 
SRSF2 
H2A(+268+292) 4 1 0 0 
H2D(+10-12) 0 1 1 0 
HTT H12A(+269+297)* 3 4 3 0 
LMNA H11A(+221+245)* 3 3 1 1 
*Not tested in this study; published results 198 
The splicing factor SRSF1 is necessary for several splicing processes, including lariat formation 199 
and 5’ss cleavage 33. In addition, SRSF1 assists in modulating 5’ss selection 33. The addition of 200 
purified SRSF1 to cultured cells favored 5’ss located more proximally to the 3’ss while lower levels 201 
of SRSF1 favored 5’ss located distal to the 3’ss 34. In our study, AOs can mask the availability of 202 
ESE motif binding sites, therefore reducing the amount of SRSF1 that can bind to the pre-mRNA. 203 
Fewer SRSF1 binding sites may drive the 5’ss preference away from the canonical splice site 204 
towards a more distal cryptic splice site.  205 
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Analysis of AO-induced changes to exonic splicing enhancer/silencer access within 206 
cryptically spliced exons 207 
It is notable that in all seven of the above examples, the cryptic splice sites observed fell within the 208 
exon, between the canonical splice sites, rather than downstream or upstream. We suggest that this 209 
is a logical consequence of the ‘exon definition’ paradigm under which the human spliceosome is 210 
thought to operate, whereby transcript sequence between the first and last exons is processed as 211 
intron unless specifically defined as being part of an internal exon 35. Because ‘intron’ is the default 212 
sequence identity under this paradigm, AO binding is therefore much more likely to diminish an 213 
existing exon signal than it is to spontaneously extend it.  214 
Because four of the seven cryptic splice sites had MaxEnt scores lower than their canonical 215 
counterparts, it was clear that our analysis would need to encompass other variables in order to 216 
explain the activation of these sites – specifically, those variables that could plausibly be altered by 217 
AO binding. We therefore attempted to model the effect that AO binding would have on both the 218 
local secondary structure of the transcript and the subsequent change in accessibility to ESE and 219 
exon splicing silencer (ESS) motifs. 220 
The ESE and ESS motifs for each cryptically spliced exon were overlaid to generate enhancer 221 
and silencer scores at each nucleotide position. These values were then “masked” by the predicted 222 
secondary structure for the exons, effectively resetting the ESE and ESS scores to zero for all 223 
nucleotides predicted to bind other nucleotides. This masking was repeated with the altered 224 
structures predicted for on-target AO binding, and the two plots were vertically aligned to allow 225 
comparison between them (Fig. 2a-e). Because the size of USH2A exon 13 (642 nt) made it 226 
impractical to visually compare changes in its ESE and ESS access in the same manner as for the 227 
other exons, we elected to present only the net changes in ESE and ESS access as a result of AO 228 
binding (Fig. 2f-g). 229 
In COL7A1 exon 15 (Fig. 2a), AO binding was predicted to increase ESE access in the retained 230 
5′ segment, as well as directly competing with ESEs in the excised 3′ segment. The net effect was 231 
a much stronger exon signal from the 5′ segment that improved the profile of the cryptic donor site. 232 
This example demonstrates that blocking an authentic donor site does not automatically activate a 233 
cryptic donor site; additional elements, including secondary structure and exon and intron definition 234 
motifs, are necessary to define the exon boundary.  235 
For SRSF2 exon 2 (Fig. 2b), the AO directly obscured the strongest enhancer peak in the 236 
excised 3’ segment and induced a moderate increase in ESE access within the retained 5’ segment. 237 
We also observed that, in the absence of AO binding, the enhancer signal in the excised 3’ segment 238 
of the exon was substantially stronger than in the rest of the exon. This may be a positively selected 239 
feature to ensure inclusion of this segment and avoidance of the cryptic splice site, though it is not 240 
clear why the very poor MaxEnt score of the cryptic donor is not a sufficient deterrent alone.  241 
In ATXN3 exon 9 (Fig. 2c), the AO binding site overlapped the cryptic donor site and caused 242 
loss of ESE access 3’ of cryptic donor and a slight increase of ESE access immediately 5′ of the 243 
cryptic donor. This, combined with the much stronger MaxEnt score of the cryptic site, may have 244 
been enough to shift exon definition to the 5’ region of the exon. 245 
In HTT exon 12 (Fig. 2d), the changes in secondary structure did not clearly favor either 246 
enhancement or silencing of the excised segment. However, ESS access was increased both 5’ and 247 
3’ of the canonical donor site, and this appears to have been sufficient to tip the balance towards 248 
the comparably strong cryptic donor splice site. A similar change appears to have occurred in LMNA 249 
exon 11 (Fig. 2e), with the exception that the cryptic donor site in this exon was much stronger than 250 
its canonical neighbor. 251 
For USH2A exon 13, there was almost no change to predicted secondary structure induced by 252 
H13A(+70+94), apart from that at the AO binding site (Fig. 2f). It therefore appears that steric blocking 253 
alone is the reason for cryptic splice site inducement in this case, though it is notable that this 254 
relatively minor change to the exon’s secondary and tertiary structure is sufficient to redirect the 255 
spliceosome to an alternative 3’ss, 490 nt downstream. This suggests that coordination between the 256 
canonical acceptor and donor sites is essential for sustaining the exon definition signal across this 257 
exon’s entire 642 nt span. However, we cannot explain why H13A(+70+94) drove use of the cryptic 258 
splice site removing 527 nt from exon 13 specifically, especially when compared to the case of the 259 
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H13A(+136+160) AO that induced use of a much stronger cryptic acceptor site only 37 nt 260 
downstream (Fig. 2g). We suggest that there may be some aspects of exon definition that are unique 261 
to internal exons as large as USH2A exon 13 and that these can only be properly understood by 262 
studying splicing in similarly sized exons from other genes. Exons longer than 500 nt, such as USH2A 263 
exon 13, typically rely on intron definition rather than exon definition in order to achieve correct 264 
splicing, but this intron-defined splicing can become inefficient when the intron size exceeds 500 nt 265 
36,37. It is possible that sporadic splice site activation in this larger exon is partly due to the inability 266 
of the spliceosome to utilize intron definition, and thus inefficiently creates exon isoforms of less 267 






Figure 2. Changes to predicted exon splicing enhancer/silencer (ESE/ESS) access in seven examples 272 
of antisense oligonucleotide (AO)-induced cryptic splicing of canonical exons. Blue lines indicate ESE 273 
access and red lines indicate ESS access (a-e), while for the 642 nt USH2A exon 13, purple indicates the net 274 
change in ESE and ESS access as a result of AO binding (f-g). Grey shading indicates pre-mRNA sequence 275 
excluded from the mature transcript. Region sizes and Maximum Entropy scores for cryptic and canonical 276 
splice sites are also shown.  277 
Conclusions 278 
Despite the small number of examples of AO-induced cryptic splicing, we observed considerable 279 
diversity in the etiology of this phenomenon. However, a common feature appears to be disruption 280 
of the exon definition signal. 281 
It is clear that canonical exon definition is achieved not by any single motif, but by the 282 
cumulative signal of multiple enhancers binding with regularity and consistency along the entire exon 283 
span. Furthermore, continuity of this enhancing signal appears to be just as important, if not more 284 
important, than its overall strength. This continuity is especially crucial when the exon contains a 285 
cryptic splice site, as this is often the only metric by which the spliceosome can distinguish the 286 





Methods  290 
Antisense oligonucleotides (AOs) 291 
Antisense oligonucleotides (AOs) comprising of 2´-O-methyl modified bases on a phosphorothioate 292 
backbone (2’-OMe PS) were synthesized by TriLink BioTechnologies (San Diego, CA) or synthesized 293 
in-house on an Expedite 8909 Nucleic Acid synthesizer (Applied Biosystems, Melbourne, Australia) 294 
using the 1 µmol thioate synthesis protocol, as described previously 38. After synthesis, the 295 
oligonucleotides were cleaved from the support following incubation in ammonium hydroxide for a 296 
minimum of 24 h at room temperature. The 2′-OMe PS AOs were subsequently desalted under 297 
sterile conditions on NAP-10 columns (GE Healthcare, Sydney, Australia) according to 298 
manufacturer’s instructions. The 2’-OMe PS AOs used in this study are listed in Table 3. 299 
Oligonucleotide nomenclature is based on that described by Aung-Htut et al. (2019) and Mann et al. 300 
(2002), indicating the intron:exon, exon or exon:intron annealing coordinates in the target gene pre-301 
mRNA 39,40.  302 
Table 3. Information for AOs 303 
















HTT H12A(+269+297)*17 CGGUGGUGGUCUGGGAGCUGUCGCUGAUG 
LMNA H11A(+221+245)*15 AGGAGGUAGGAGCGGGUGACCAGAU 
* Not tested in this study; published results 304 
Cell culture and transfection 305 
All cell culture reagents were purchased from Gibco, (ThermoFisher Scientific, Scoresby, Australia), 306 
unless otherwise stated. Primary dermal fibroblasts derived from a healthy volunteer after informed 307 
consent (The University of Western Australia Human Research Ethics Committee approval 308 
RA/4/1/2295; Murdoch University Human Research Ethics Committee approval 2013/156) were 309 
propagated in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 1% GlutaMax™-I 310 
and 10% foetal bovine serum (FBS) (Scientifix, Cheltenham, Australia) at 37°C in a 5% CO2 311 
atmosphere. Cells were seeded in 24-well plates (1.8 x 104 cells/well) in DMEM supplemented with 312 
10% FBS for 24 hours before transfection. The human hepatocarcinoma cell line, Huh7, was 313 
supplied by the JCRB Cell Bank (Osaka, Japan) and purchased from CellBank Australia (Westmead, 314 
NSW, Australia). These cells were maintained in DMEM supplemented with 10% FBS at 37°C in a 315 
5% CO2 atmosphere. Huh7 cells were seeded in 24-well plates (5 x 104 cells/well) in propagation 316 
media for 24 hours before transfection. 317 
Fibroblast and Huh7 cells were transfected with 2´-OMe PS AO-Lipofectamine 3000 (Thermo 318 
Fisher Scientific) lipoplexes in Opti-MEM (Gibco) according to the manufacturer’s instructions, at 319 
various concentrations in duplicate wells, and the cells were then incubated at 37˚C for 24 hours 320 
before RNA extraction. The negative control oligo (sequence from Gene Tools, LLC synthesized as 321 
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a 2´-OMe PS AO), which targets a human beta-globin intron mutation, was used as a negative 322 
control.  323 
Molecular analysis 324 
After harvesting the cells, total RNA was extracted using MagMax™ nucleic acid isolation kit 325 
(AM1830; Thermo Fisher Scientific) according to manufacturer’s instructions and included the 326 
DNase treatment step. Molecular analyses were accomplished using three different systems 327 
optimized for different gene targets. SuperScript™ III One-Step RT-PCR System with Platinum™ 328 
Taq DNA Polymerase (Thermo Fisher Scientific) was used to synthesize and amplify cDNA from 50 329 
ng of total RNA in a single step. Nested PCR was necessary to amplify the USH2A transcripts. 330 
Briefly, after 20 cycles of amplification, one µl aliquot was removed and subjected to nested PCR 331 
for 25 cycles using AmpliTaq Gold (Thermo Fisher Scientific) and an inner primer set. For regions 332 
with a high GC-content that are more difficult to amplify, SuperScript™ IV First-Strand Synthesis 333 
System and random hexamers (Thermo Fisher Scientific) were used to synthesize cDNA from 334 
harvested total RNA, and approximately 50 ng of cDNA was used as a template for PCR amplification 335 
using the TaKaRa LA Taq® DNA Polymerase with GC Buffer II system (Takara Bio USA, Inc., Clayton, 336 
Australia). PCR systems, conditions and primers used to assess splice modulation across the 337 
different gene transcripts are summarized in Table 4. 338 
Amplified RT-PCR products were resolved on 2% agarose gels by electrophoresis in Tris-339 
acetate ethylenediaminetetraacetic acid buffer, compared to a 100 bp DNA size standard 340 
(Geneworks, Adelaide, Australia). Relative transcript abundance was estimated by densitometry on 341 
images captured by the Fusion FX system (Vilber Lourmat, Marne-la-Vallée, France) using Fusion-342 
Capt software and ImageJ (version 1.8.0_112) software for densitometry analysis. To identify RT-343 
PCR products, the amplicons were first isolated by bandstab 41, followed by template preparation 344 
using Diffinity RapidTip for PCR Purification (Diffinity Genomics, Inc., West Henrietta, NY) and DNA 345 
sequencing, performed by the Australian Genome Research Facility Ltd. (Nedlands, Australia).  346 



















55˚C (30 min) and 
94˚C (2 min); 28 
cycles of 94˚C (30s), 
55˚C (30s) and 68˚C 
(1.5 min) 
Exon 11R AGCTGCCTGAAGCATGTCTTCTT 
COL7A1 
(NM_000094.4) 




55˚C (30 min) and 
94˚C (2 min); 30 
cycles of 94˚C (30s), 
60˚C (30s) and 68˚C 
(1.5 min) 
Exon 19R TGGGAGTATCTGGTGCCTCA 
SRSF2 
(XR_429913.4) 





94˚C (1 min); 32 
cycles of 94˚C (30s), 
62˚C (30s) and 72˚C 
(4 min) 
Exon 4R CTCAACTGCTACACAACTGC 
USH2A 
(NM_206933.4) 




55˚C (30 min) and 
94˚C (2 min); 20 
cycles of 94˚C (15s), 
60˚C (30s) and 68˚C 
(1 min) 
Exon 15R GACAGGTTTCATTCAAGGCTCC 




94˚C (5 min); 25 
cycles of 94˚C (30s), 
Exon 14R CAAACACACTGACCAGTCAGG 
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60˚C (30s) and 72˚C 
(1 min); 72˚C (5 min) 
In silico analysis 348 
Basic Local Alignment Search Tool (BLAST) 42 was used to compare amplicon sequences to the 349 
reference mRNA sequences (accession numbers: Table 4). Sequences for each cryptically spliced 350 
exon and +/-20 nt of flanking intron were input to Human Splice Finder 30 which generated a JSON 351 
file with the locations of every detected ESE and ESS motif, as well as predicted acceptor and donor 352 
splice sites. Raw text from this JSON file was then imported into a custom-made spreadsheet (see 353 
Supplementary Material) that used this data to assign an ESE and an ESS score to each nucleotide 354 
of the sequence, under the following rationale: 355 
 356 
ESE score: +1/n for each overlapping ESE motif, where n = ESE motif length; 357 
  358 
ESS score: -1/n for each overlapping ESS motif, where n = ESS motif length. 359 
  360 
For example, a nucleotide that fell within two six nt ESE motifs and one eight nt ESS motif would 361 
be assigned an ESE score of 0.333 (2 x 1/6) and an ESS score of -0.125 (1 x -1/8). 362 
 363 
Predicted centroid normal RNA folding was calculated for the sequence of each cryptically 364 
spliced exon with +/-70 nt flanking intron, using RNAfold 43 with the “avoid isolated base pairs” 365 
option. Predicted centroid AO-induced folding was calculated for each exon using the same 366 
sequence and settings as for normal folding, but with an additional constraint mask that prohibited 367 
binding within the AO target sites. 368 
 369 
Data availability 370 
All data generated or analyzed during this study are included in this published article (and its 371 
Supplementary Information file). 372 
  373 
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Supplementary materials 374 
 375 
Supplementary Figure 1. Analysis of antisense oligonucleotide-mediated splice switching in 376 
SRSF2 gene transcripts. (a) Full gel image of reverse transcription-PCR analysis after transfection 377 
with antisense oligonucleotides (AOs), at various nM concentrations indicated above the gel image. 378 
(b) Alternative transcript exon composition before and after AO treatment. Blue boxes represent 379 
exons, lines between the boxes represent introns, dashed lines above and below represent various 380 
splicing events, red polygons represent termination codons, pink boxes represent the exon portion 381 
removed after the activation of a cryptic splice site, pink polygons represent termination codons 382 
removed after cryptic splice site activation. Multiple transcript isoforms noted as T### according to 383 
Ensembl. Question mark (?) indicates an amplicon that could not be succesfully isolated and 384 
sequenced. NC, negative control sequence synthesized as 2’-OMe PS; UT, untreated; 100 bp, 100 385 
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